These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 32140997)

  • 1. Therapeutic Potential of Citrulline as an Arginine Supplement: A Clinical Pharmacology Review.
    Rashid J; Kumar SS; Job KM; Liu X; Fike CD; Sherwin CMT
    Paediatr Drugs; 2020 Jun; 22(3):279-293. PubMed ID: 32140997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondria: role of citrulline and arginine supplementation in MELAS syndrome.
    El-Hattab AW; Emrick LT; Chanprasert S; Craigen WJ; Scaglia F
    Int J Biochem Cell Biol; 2014 Mar; 48():85-91. PubMed ID: 24412347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Citrulline and arginine utility in treating nitric oxide deficiency in mitochondrial disorders.
    El-Hattab AW; Emrick LT; Craigen WJ; Scaglia F
    Mol Genet Metab; 2012 Nov; 107(3):247-52. PubMed ID: 22819233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired nitric oxide production in children with MELAS syndrome and the effect of arginine and citrulline supplementation.
    El-Hattab AW; Emrick LT; Hsu JW; Chanprasert S; Almannai M; Craigen WJ; Jahoor F; Scaglia F
    Mol Genet Metab; 2016 Apr; 117(4):407-12. PubMed ID: 26851065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 8-year retrospective analysis of intravenous arginine therapy for acute metabolic strokes in pediatric mitochondrial disease.
    Ganetzky RD; Falk MJ
    Mol Genet Metab; 2018 Mar; 123(3):301-308. PubMed ID: 29428506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arginine and citrulline for the treatment of MELAS syndrome.
    El-Hattab AW; Almannai M; Scaglia F
    J Inborn Errors Metab Screen; 2017 Jan; 5():. PubMed ID: 28736735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of citrulline and arginine supplementation on lactic acidemia in MELAS syndrome.
    El-Hattab AW; Emrick LT; Williamson KC; Craigen WJ; Scaglia F
    Meta Gene; 2013 Dec; 1():8-14. PubMed ID: 25411654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic use of citrulline in cardiovascular disease.
    Romero MJ; Platt DH; Caldwell RB; Caldwell RW
    Cardiovasc Drug Rev; 2006; 24(3-4):275-90. PubMed ID: 17214603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of impaired nitric oxide production in MELAS syndrome with citrulline and arginine supplementation.
    El-Hattab AW; Hsu JW; Emrick LT; Wong LJ; Craigen WJ; Jahoor F; Scaglia F
    Mol Genet Metab; 2012 Apr; 105(4):607-14. PubMed ID: 22325939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Nitric Oxide Production in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes Syndrome with the Use of a Stable Isotope Tracer Infusion Technique.
    El-Hattab AW; Jahoor F
    J Nutr; 2017 Jul; 147(7):1251-1257. PubMed ID: 28515163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. l-Citrulline Supplementation: Impact on Cardiometabolic Health.
    Allerton TD; Proctor DN; Stephens JM; Dugas TR; Spielmann G; Irving BA
    Nutrients; 2018 Jul; 10(7):. PubMed ID: 30029482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral citrulline as arginine precursor may be beneficial in sickle cell disease: early phase two results.
    Waugh WH; Daeschner CW; Files BA; McConnell ME; Strandjord SE
    J Natl Med Assoc; 2001 Oct; 93(10):363-71. PubMed ID: 11688916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism.
    Schwedhelm E; Maas R; Freese R; Jung D; Lukacs Z; Jambrecina A; Spickler W; Schulze F; Böger RH
    Br J Clin Pharmacol; 2008 Jan; 65(1):51-9. PubMed ID: 17662090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Citrulline a more suitable substrate than arginine to restore NO production and the microcirculation during endotoxemia.
    Wijnands KA; Vink H; Briedé JJ; van Faassen EE; Lamers WH; Buurman WA; Poeze M
    PLoS One; 2012; 7(5):e37439. PubMed ID: 22666356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-Arginine Affects Aerobic Capacity and Muscle Metabolism in MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) Syndrome.
    Rodan LH; Wells GD; Banks L; Thompson S; Schneiderman JE; Tein I
    PLoS One; 2015; 10(5):e0127066. PubMed ID: 25993630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supplemental Citrulline Is More Efficient Than Arginine in Increasing Systemic Arginine Availability in Mice.
    Agarwal U; Didelija IC; Yuan Y; Wang X; Marini JC
    J Nutr; 2017 Apr; 147(4):596-602. PubMed ID: 28179487
    [No Abstract]   [Full Text] [Related]  

  • 17. MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options.
    El-Hattab AW; Adesina AM; Jones J; Scaglia F
    Mol Genet Metab; 2015; 116(1-2):4-12. PubMed ID: 26095523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute ingestion of citrulline stimulates nitric oxide synthesis but does not increase blood flow in healthy young and older adults with heart failure.
    Kim IY; Schutzler SE; Schrader A; Spencer HJ; Azhar G; Deutz NE; Wolfe RR
    Am J Physiol Endocrinol Metab; 2015 Dec; 309(11):E915-24. PubMed ID: 26442881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetic nephropathy is resistant to oral L-arginine or L-citrulline supplementation.
    You H; Gao T; Cooper TK; Morris SM; Awad AS
    Am J Physiol Renal Physiol; 2014 Dec; 307(11):F1292-301. PubMed ID: 25320354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric oxide precursors and congenital heart surgery: a randomized controlled trial of oral citrulline.
    Smith HA; Canter JA; Christian KG; Drinkwater DC; Scholl FG; Christman BW; Rice GD; Barr FE; Summar ML
    J Thorac Cardiovasc Surg; 2006 Jul; 132(1):58-65. PubMed ID: 16798303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.